Dexamethasone in Cryptococcal Meningitis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Listed as NCT00000776, this PHASE2 trial focuses on HIV Infections and Meningitis, Cryptococcal and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Birmingham, United States
- • Brooklyn, United States
- • Buffalo, United States
- • Chicago, United States
- • Columbus, United States
- • Miami, United States
- • New York, United States
- • San Juan, Puerto Rico
- • The Bronx, United States
- • Washington D.C., United States